Ocular Therapeutix, Inc.OCULNASDAQ
LOADING
|||
EPS Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year earnings per share growth rate
Latest
23.68%
↑ 262% above average
Average (39q)
-14.58%
Historical baseline
Range
High:77.69%
Low:-536.84%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q4 2025 | 23.68% |
| Q3 2025 | 2.56% |
| Q2 2025 | -2.63% |
| Q1 2025 | -31.03% |
| Q4 2024 | -31.82% |
| Q3 2024 | 15.38% |
| Q2 2024 | 46.94% |
| Q1 2024 | -133.33% |
| Q4 2023 | 22.22% |
| Q3 2023 | -3.85% |
| Q2 2023 | 33.33% |
| Q1 2023 | -56.00% |
| Q4 2022 | 19.35% |
| Q3 2022 | -14.81% |
| Q2 2022 | -12.50% |
| Q1 2022 | 0.00% |
| Q4 2021 | 7.69% |
| Q3 2021 | 3.70% |
| Q2 2021 | 0.00% |
| Q1 2021 | 77.69% |
| Q4 2020 | -536.84% |
| Q3 2020 | 70.31% |
| Q2 2020 | -56.10% |
| Q1 2020 | 24.07% |
| Q4 2019 | -35.00% |
| Q3 2019 | 29.82% |
| Q2 2019 | -39.02% |
| Q1 2019 | 2.38% |
| Q4 2018 | -10.53% |
| Q3 2018 | -2.70% |
| Q2 2018 | 7.50% |
| Q1 2018 | 9.09% |
| Q4 2017 | 18.52% |
| Q3 2017 | 15.62% |
| Q2 2017 | -10.34% |
| Q1 2017 | -11.54% |
| Q4 2016 | -33.33% |
| Q3 2016 | 15.22% |
| Q2 2016 | -4.55% |
| Q1 2016 | -2.33% |